Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lomitapide
Drug ID BADD_D01311
Description Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Indications and Usage Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
Marketing Status approved; investigational
ATC Code C10AX12
DrugBank ID DB08827
KEGG ID D09637
MeSH ID C473731
PubChem ID 9853053
TTD Drug ID D0H8VY
NDC Product Code Not Available
UNII 82KUB0583F
Synonyms BMS201038 | BMS-201038 | BMS 201038 | lomitapide | Juxtapid | AEGR 733 | AEGR733 | AEGR-733
Chemical Information
Molecular Formula C39H37F6N3O2
CAS Registry Number 182431-12-5
SMILES C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C (=O)NCC(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint swelling15.01.02.004--Not Available
Laryngeal pain22.12.03.010--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000084%
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000073%Not Available
Liver disorder09.01.08.0010.000167%Not Available
Liver function test abnormal13.03.04.030--Not Available
Malaise08.01.01.0030.001407%
Middle insomnia19.02.01.003; 17.15.03.0030.000084%Not Available
Migraine24.03.05.003; 17.14.02.0010.000084%Not Available
Muscle atrophy17.05.03.004; 15.05.03.0030.000073%Not Available
Muscle spasms15.05.03.0040.000548%
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000167%
Musculoskeletal pain15.03.04.0070.000218%
Myalgia15.05.02.0010.000469%
Myocardial infarction24.04.04.009; 02.02.02.0070.000118%
Nasal congestion22.04.04.0010.000146%
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.0010.003412%
Neck pain15.03.04.0090.000156%
Nervous system disorder17.02.10.001--Not Available
Neutrophil count decreased13.01.06.010--
Nightmare19.02.03.0030.000182%Not Available
Nocturia20.02.03.0010.000109%Not Available
Osteoporosis14.04.04.002; 15.02.03.0020.000073%
Pain in extremity15.03.04.0100.000585%
Palpitations02.11.04.0120.000141%
Pancreatitis07.18.01.0010.000021%
Papule23.03.03.038--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene